Mitochondria–directed antioxidants (MnSOD mimetics) and classic mitochondrial antioxidants (coenzyme Q10 or CoQ10, α-lipoic acid) have a substantial preclinical and some clinical track record in limiting mitochondrial oxidative injury and improving bioenergetics in mitochondrial disease contexts; these could be repurposed or trialed as adjuncts in WD to reduce ROS–mediated respiratory chain damage while chelation therapies lower copper load. The gene discussed is SOD2; the disease is mitochondrial disease.